- Home
- PSNL
PSNL
Personalis Inc.
as 02-21-2025 4:00pm EST
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Upcoming Earnings Alert:
Get ready for potential market movements as Personalis Inc. PSNL prepares to release earnings report on 27 Feb 2025.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 460.7M | IPO Year: | 2019 |
| Target Price: | $7.81 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $7.20 | Next Earning Date: | 02-27-2025 |
| Revenue: | $87,489,000 | Revenue Growth: | 24.05% |
| Revenue Growth (this year): | 16% | Revenue Growth (next year): | 1.29% |
Stock Insider Trading Activity of Personalis Inc. (PSNL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | Jan 28 '25 | Sell | $5.79 | 519 | $3,005.01 | 123,367 | |
| Tachibana Aaron | PSNL | CFO AND COO | Jan 28 '25 | Sell | $5.79 | 708 | $4,099.32 | 166,390 | |
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | Dec 16 '24 | Sell | $3.82 | 4,834 | $18,465.88 | 123,367 | |
| Tachibana Aaron | PSNL | CFO AND COO | Dec 16 '24 | Sell | $3.82 | 6,865 | $26,224.30 | 166,390 | |
| Moore Stephen Michael | PSNL | SVP and Chief Legal Officer | Dec 16 '24 | Sell | $3.82 | 1,513 | $5,779.66 | 65,875 |
Latest Personalis Inc. News
PSNL Breaking Stock News: Dive into PSNL Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Business Wire
4 days ago
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
Business Wire
9 days ago
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
Business Wire
25 days ago
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Zacks
a month ago
Personalis (PSNL) Upgraded to Buy: Here's Why
Medical Device Network
a month ago
Researchers find ctDNA test predicts lung cancer outcomes in study
MT Newswires
a month ago
Personalis Says Study Shows NeXT Personal Test's 'High Sensitivity' for Lung Cancer Detection
Business Wire
a month ago
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
Compare PSNL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSNL Personalis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.